Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#71 / 141 Total
PLCE - Childrens Place Inc - Stock Price Chart
TickerPLCE [NASD, RUT]
CompanyChildrens Place Inc
CountryUSA
IndustryApparel Retail
Market Cap89.48MEPS (ttm)-6.20
P/E-EPS this Y-4225.00%
Forward P/E1074.96EPS next Y100.19%
PEG-EPS past 5Y-
P/S0.06EPS next 5Y-7.10%
P/B0.76EPS Q/Q-6.34%
Dividend-Sales Q/Q-5.67%
Insider Own61.71%Inst Own81.14%
Insider Trans132.03%Inst Trans-8.68%
Short Float65.77%EarningsNov 16/b
Analyst Recom3.00Target Price10.00
Avg Volume1.66M52W Range6.98 - 38.03
Apr-24-24Upgrade B. Riley Securities Sell → Neutral $12 → $7
The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children's Place, Baby Place, and Gymboree. It operates through The Children's Place U.S. and The Children's Place International segments. The Children's Place U.S. segment refers to the company's U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children's Place International segment is involved in the Canadian-based stores, revenue from the company's Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mithaq Capital SPC10% OwnerFeb 13 '24Buy11.15966,34410,779,0276,751,387Feb 15 03:57 PM
Mithaq Capital SPC10% OwnerFeb 12 '24Buy15.801,566,47524,749,5254,663,743Feb 14 07:51 PM
Mithaq Capital SPC10% OwnerFeb 09 '24Buy11.021,849,39720,387,1783,097,268Feb 13 09:11 PM
ELFERS JANE TPresident and CEOJul 05 '23Buy23.7043,0001,019,100370,033Jul 06 08:30 AM
FOA - Finance of America Companies Inc - Stock Price Chart
TickerFOA [NYSE, RUT]
CompanyFinance of America Companies Inc
CountryUSA
IndustryCredit Services
Market Cap48.29MEPS (ttm)-1.34
P/E-EPS this Y-108.84%
Forward P/E1.60EPS next Y981.10%
PEG-EPS past 5Y-528.03%
P/S1.58EPS next 5Y-
P/B0.21EPS Q/Q129.66%
Dividend-Sales Q/Q-69.36%
Insider Own69.61%Inst Own20.73%
Insider Trans0.00%Inst Trans-0.17%
Short Float3.72%EarningsMar 06/a
Analyst Recom1.50Target Price1.75
Avg Volume88.40K52W Range0.51 - 2.09
Finance of America Cos. Inc. engages in the provision of mortgage loans, reverse mortgage loans, and business purpose loans to residential real estate investors. It offers a vertically integrated lending and services platform that connects borrowers with investors. The company was founded on October 9, 2020 and is headquartered in Plano, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sieffert Kristen NPresidentApr 01 '24Option Exercise0.00360,6980565,216Apr 03 04:42 PM
Thornock Tai A.Chief Accounting OfficerApr 01 '24Option Exercise0.0084,4940149,255Apr 03 04:38 PM
Richmond LaurenChief Legal OfficerApr 01 '24Option Exercise0.0095,1810198,480Apr 03 04:36 PM
Prahm JeremyChief Investment OfficerApr 01 '24Option Exercise0.00772,49201,115,176Apr 03 04:34 PM
Fleming GrahamChief Executive OfficerApr 01 '24Option Exercise0.00892,89301,401,158Apr 03 04:32 PM
FOXF - Fox Factory Holding Corp - Stock Price Chart
TickerFOXF [NASD, RUT]
CompanyFox Factory Holding Corp
CountryUSA
IndustryAuto Parts
Market Cap1.67BEPS (ttm)2.84
P/E14.02EPS this Y-38.54%
Forward P/E10.48EPS next Y56.80%
PEG0.93EPS past 5Y5.71%
P/S1.14EPS next 5Y15.00%
P/B1.37EPS Q/Q-92.32%
Dividend-Sales Q/Q-18.63%
Insider Own0.30%Inst Own102.14%
Insider Trans0.00%Inst Trans0.56%
Short Float6.21%EarningsMay 02/a
Analyst Recom2.33Target Price56.88
Avg Volume681.72K52W Range40.15 - 117.68
Fox Factory Holding Corp. engages in designing, engineering, manufacturing and marketing performance ride dynamics products. The firm offers bicycles, side-by-sides and on-road vehicles with off-road capabilities, off-road vehicles and trucks, all - terrain vehicles, snowmobiles, specialty vehicles and applications and motorcycles. It operates through the following geographical segments: North America, Asia, Europe and Rest of the World. The company was founded on December 28, 2007 and is headquartered in Duluth, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DUNCAN THOMAS E.DirectorSep 01 '23Sale111.911,427159,6968,559Sep 06 04:04 PM
Stecher PaulSEE REMARKS (A)Aug 25 '23Sale107.002,300246,10016,360Aug 29 04:02 PM
DENNISON MICHAEL C.Chief Executive OfficerAug 10 '23Sale114.009,1291,040,70670,795Aug 15 04:01 PM
Tutton ChristopherSEE REMARKS (A)Jun 13 '23Sale94.422,279215,18313,242Jun 15 04:01 PM
MENDENHALL DUDLEY WDirectorJun 07 '23Sale95.121,304124,03610,500Jun 09 04:01 PM
OOMA - Ooma Inc - Stock Price Chart
TickerOOMA [NYSE, RUT]
CompanyOoma Inc
CountryUSA
IndustryTelecom Services
Market Cap177.28MEPS (ttm)-0.03
P/E-EPS this Y-9.89%
Forward P/E10.89EPS next Y15.86%
PEG-EPS past 5Y46.39%
P/S0.75EPS next 5Y47.70%
P/B2.23EPS Q/Q-604.17%
Dividend-Sales Q/Q9.17%
Insider Own9.96%Inst Own72.96%
Insider Trans0.27%Inst Trans0.02%
Short Float1.59%EarningsMar 05/a
Analyst Recom1.00Target Price15.60
Avg Volume86.39K52W Range6.74 - 15.66
Ooma, Inc. engages in the provision of platforms for cloud-based communications solutions, smart security and other connected services. It helps create smart workplaces and homes by providing communications, monitoring, security, automation, productivity, and networking infrastructure applications. Its products and services include Ooma business and Ooma residential. Ooma business offers small business phone services and enterprise communications. Ooma residential deals with phone services and smart security, and the Talkatone mobile app. The company was founded by Andrew Frame, Dennis Peng and Michael Cerda on November 19, 2003 and is headquartered in Sunnyvale, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sabharwal NamrataChief Accounting OfficerDec 29 '23Sale10.728,04486,23634,948Jan 03 06:07 PM
STANG ERIC BCEO and Pres.Dec 15 '23Buy10.085,00050,400393,125Dec 19 04:29 PM
STANG ERIC BCEO and Pres.Dec 13 '23Buy9.8510,00098,486388,125Dec 15 07:42 PM
Pearce William DDirectorJun 16 '23Sale14.055,10071,672147,368Jun 21 05:25 PM
Gustke James A.Vice President of MarketingJun 08 '23Sale13.2515,000198,795160,010Jun 09 07:14 PM
VMAR - Vision Marine Technologies Inc - Stock Price Chart
TickerVMAR [NASD]
CompanyVision Marine Technologies Inc
CountryCanada
IndustryRecreational Vehicles
Market Cap6.30MEPS (ttm)-1.01
P/E-EPS this Y59.54%
Forward P/E-EPS next Y-19.78%
PEG-EPS past 5Y-146.70%
P/S1.65EPS next 5Y-
P/B1.39EPS Q/Q6.15%
Dividend-Sales Q/Q-12.08%
Insider Own85.09%Inst Own5.34%
Insider Trans0.00%Inst Trans1.31%
Short Float15.79%EarningsApr 15/b
Analyst Recom1.00Target Price3.44
Avg Volume64.15K52W Range0.51 - 5.60
Vision Marine Technologies, Inc. engages in the design, development, and manufacturing of electric outboard powertrain systems and electric boats. It operates through the Sale of Electric Boats and Rental of Electric Boats segments. The Sale of Electric Boats segment involves the manufacture of customized boats for the consumer market, sale of parts, and maintenance. The Rental of electric boats segment includes short-term rental operations and boat club membership. The company was founded by Patrick Bobby and Alexander Mongeon in 1995 and is headquartered in Boisbriand, Canada.
GRI - GRI Bio Inc - Stock Price Chart
TickerGRI [NASD]
CompanyGRI Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap1.40MEPS (ttm)-63.58
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y26.64%
P/S-EPS next 5Y-
P/B1.09EPS Q/Q87.41%
Dividend-Sales Q/Q-
Insider Own6.23%Inst Own0.86%
Insider Trans0.00%Inst Trans7.63%
Short Float0.61%EarningsApr 01/b
Analyst Recom1.00Target Price2520.00
Avg Volume762.06K52W Range0.42 - 93.31
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
PLRX - Pliant Therapeutics Inc - Stock Price Chart
TickerPLRX [NASD, RUT]
CompanyPliant Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap716.86MEPS (ttm)-2.75
P/E-EPS this Y-19.40%
Forward P/E-EPS next Y-7.78%
PEG-EPS past 5Y-22.68%
P/S453.71EPS next 5Y-
P/B1.51EPS Q/Q4.52%
Dividend-Sales Q/Q-100.00%
Insider Own12.44%Inst Own95.70%
Insider Trans-0.80%Inst Trans36.14%
Short Float14.45%EarningsFeb 27/a
Analyst Recom1.00Target Price43.00
Avg Volume362.98K52W Range12.00 - 30.85
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coulie BernardPresident and CEOJan 17 '24Sale17.2325,721443,173316,382Jan 19 05:19 PM
Lefebvre EricChief Medical OfficerJan 17 '24Sale17.2310,295177,383156,920Jan 19 05:18 PM
Hull HansChief Business OfficerJan 17 '24Sale17.239,786168,613185,069Jan 19 05:19 PM
Cummings Keith LamontChief Financial OfficerJan 17 '24Sale17.239,781168,527194,605Jan 19 05:19 PM
Ouimette MikeGeneral Counsel & Corp. Sec'yJan 17 '24Sale17.235,19789,54455,246Jan 19 05:11 PM
BCRX - Biocryst Pharmaceuticals Inc. - Stock Price Chart
TickerBCRX [NASD, RUT]
CompanyBiocryst Pharmaceuticals Inc.
CountryUSA
IndustryBiotechnology
Market Cap867.89MEPS (ttm)-1.18
P/E-EPS this Y42.53%
Forward P/E-EPS next Y48.04%
PEG-EPS past 5Y-3.73%
P/S2.62EPS next 5Y44.80%
P/B-EPS Q/Q19.91%
Dividend-Sales Q/Q17.42%
Insider Own3.68%Inst Own84.59%
Insider Trans0.00%Inst Trans-1.64%
Short Float17.32%EarningsMay 06/b
Analyst Recom1.33Target Price13.82
Avg Volume3.16M52W Range4.27 - 9.06
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SANDERS MACHELLEDirectorJun 15 '23Sale7.984,00031,92025,611Jun 15 04:37 PM
Hutson Nancy JDirectorJun 14 '23Sale8.0412,866103,44381,818Jun 15 04:33 PM
GNLX - Genelux Corp - Stock Price Chart
TickerGNLX [NASD, RUT]
CompanyGenelux Corp
CountryUSA
IndustryBiotechnology
Market Cap92.70MEPS (ttm)-1.10
P/E-EPS this Y24.78%
Forward P/E-EPS next Y-35.24%
PEG-EPS past 5Y-23.84%
P/S545.30EPS next 5Y-
P/B4.75EPS Q/Q-77.51%
Dividend-Sales Q/Q-100.00%
Insider Own26.07%Inst Own21.66%
Insider Trans-3.88%Inst Trans-
Short Float10.24%EarningsApr 01/b
Analyst Recom1.00Target Price26.00
Avg Volume138.47K52W Range3.33 - 40.98
Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Szalay Aladar10% OwnerApr 24 '24Sale3.508,06428,2511,255,730Apr 24 05:50 PM
Szalay Aladar10% OwnerApr 23 '24Sale3.4922,00076,8001,263,794Apr 24 05:50 PM
Szalay Aladar10% OwnerApr 22 '24Sale3.5314,33150,5971,285,794Apr 24 05:50 PM
Szalay Aladar10% OwnerApr 17 '24Sale3.7122,73784,4251,300,125Apr 18 05:00 PM
Szalay Aladar10% OwnerApr 16 '24Sale3.5348,683171,8021,322,862Apr 18 05:00 PM
PTPI - Petros Pharmaceuticals Inc - Stock Price Chart
TickerPTPI [NASD]
CompanyPetros Pharmaceuticals Inc
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap4.36MEPS (ttm)-6.21
P/E-EPS this Y8.10%
Forward P/E-EPS next Y29.28%
PEG-EPS past 5Y-
P/S0.63EPS next 5Y-
P/B0.19EPS Q/Q65.49%
Dividend-Sales Q/Q214.88%
Insider Own39.80%Inst Own1.70%
Insider Trans0.00%Inst Trans0.76%
Short Float1.69%Earnings-
Analyst Recom1.00Target Price4.00
Avg Volume970.37K52W Range0.63 - 6.35
Apr-23-24 09:15AM Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health (ACCESSWIRE)
Apr-16-24 09:15AM Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) (ACCESSWIRE) -9.97%
Apr-02-24 09:53AM PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -23.57%
09:15AM Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status (ACCESSWIRE)
Mar-19-24 09:00AM Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider (ACCESSWIRE)
Mar-11-24 07:00AM BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc (News Direct)
Feb-14-24 09:15AM Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider (ACCESSWIRE)
Jan-24-24 09:15AM Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch (ACCESSWIRE) -8.00%
Jan-17-24 09:00AM Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch (ACCESSWIRE)
Dec-12-23 10:00AM Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status (ACCESSWIRE) +7.33%
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.
134567891011121315